Voices
Vivek Subbiah: Have Orphans in Rare Tumor Precision Oncology Been Adopted?
Vivek Subbiah/LinkedIn

Vivek Subbiah: Have Orphans in Rare Tumor Precision Oncology Been Adopted?

Vivek Subbiah, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute (SCRI), wrote on his X page.

“Hot off the press at Cell Journal.

Pleased to share our Friday release for your weekend read:

“Precision oncology in rare tumors: Have the orphans been adopted?” – with Dr Razelle Kurzrock.”

rare tumor

Read more articles featuring Vivek Subbiah in OncoDaily.

 

cancer OncoDaily Oncology Precision Oncology Rare Tumors Razelle Kurzrock Sarah Cannon Research Institute Vivek Subbiah